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PVascular Risk Factors
Glomerular Filtration Rate and N-Terminal
Pro-Brain Natriuretic Peptide as Predictors
of Cardiovascular Mortality in Vascular Patients
Ramin Shadman, MD, Matthew A. Allison, MD, MPH, Michael H. Criqui, MD, MPH
San Diego, California
Objectives The purpose of this work was to assess the prognostic role of glomerular filtration rate (GFR) and NT-terminal
pro-B-type natriuretic peptide (NT-proBNP) for mortality end points in the vascular population.
Background The GFR and NT-proBNP have been shown to predict mortality end points in free-living and limited vascular pop-
ulations, independent of traditional risk factors. However, their prognostic power in an unrestricted vascular pop-
ulation is poorly understood.
Methods A total of 412 subjects from a vascular cohort with a history of either peripheral arterial disease (PAD) and/or
other cardiovascular disease (CVD) were included in this prospective cohort analysis and followed for an average
of 6.7 years. Outcome variables were all-cause mortality, ischemic heart disease (IHD) mortality, and any cardio-
vascular mortality. The prognostic roles of GFR and NT-proBNP levels were determined using multivariate sur-
vival analysis.
Results Higher GFR (per 10 ml/min/1.73 m2) was significantly protective for all-cause mortality (hazard ratio [HR] 0.81,
p  0.001), IHD mortality (HR 0.82, p  0.008), and CVD mortality (HR 0.84, p  0.005). Conversely,
NT-proBNP was not a significant predictor of any mortality end point. The GFR showed the strongest association
in subjects with a history of other CVD. Although NT-proBNP did not demonstrate a significant prognostic role in
any of the subgroups, the data were suggestive for patients with PAD alone.
Conclusions Glomerular filtration rate was a robust predictor of all-cause, IHD, and cardiovascular mortality in the vascular
population, particularly in those with a history of other CVD, while NT-proBNP showed a suggestive association
limited to the group with PAD only. These findings suggest that these markers must be selectively applied in the
vascular population for greatest clinical utility. (J Am Coll Cardiol 2007;49:2172–81) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.047s
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ieripheral arterial disease (PAD) affects approximately 8
illion individuals in the U.S., and its presence has been
hown to convey an increased risk of mortality and future
ardiovascular events (1–4). However, in the clinical setting,
elatively little is known about novel risk factors for cardio-
ascular mortality in vascular patients with a high prevalence
f PAD. In particular, the measurement of renal function
nd B-type natriuretic peptide (BNP) have both received
ncreasing interest in recent years because of the ease of their
easurement in the clinical setting and their demonstrated
rognostic power in free-living and some clinical popula-
ions (5–12).
B-type natriuretic peptide is a peptide hormone that is
eleased from the cardiac ventricle as a result of myocyte
rom the University of California San Diego, San Diego, California. Peter A.
cCullough, MD, served as Guest Editor for this paper.i
Manuscript received October 10, 2006; revised manuscript received February 1,
007, accepted February 6, 2007.tretch and is predominantly cleared by the kidneys. It
as been postulated and widely believed that in response
o increased intravascular volume, there is increased
entricular wall stretch and release of BNP into the
irculation, where it has numerous systemic effects in-
luding vasodilatation, natriuresis, and inhibition of both
he sympathetic nervous system and renin-angiotensin-
ldosterone system (9). Importantly, numerous studies
ave demonstrated that BNP is a robust predictor of
ll-cause and cardiovascular (CVD) mortality in various
ree-living and patient populations (6,7,9,12–15). Simi-
arly, the relationship between glomerular filtration rate
GFR), all-cause mortality, and cardiovascular mortality
as been demonstrated in the general population and in
atients with critical leg ischemia (10,11,16 –18). Various
echanistic theories for the accelerated vascular disease
n patients with renal impairment have been postulated,
ncluding endothelial dysfunction, reduced endothelial
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June 5, 2007:2172–81 GFR and Cardiovascular Mortalityntioxidant capacity, dyslipidemia, and chronic inflam-
atory activity (19 –21).
To date, there is relatively limited understanding of the
tility of these 2 prognostic factors in patients with known
ascular disease. Prior studies have been limited by absent or
ncomplete adjustment for renal function, which can dra-
atically affect BNP levels, the exclusion of subsets of the
ascular patient population with relatively common condi-
ions, such as those with congestive heart failure (CHF),
hort follow-up periods, or analyses failing to stratify pa-
ients according to the nature of their vascular disease
istory (7,22–24). Hence, we designed this study to better
xamine the role of GFR and BNP in predicting cardiovas-
ular and all-cause mortality in patients with a history of
nown vascular disease.
ethods
tudy population. The participants in this study included
12 patients who had visited the San Diego Veterans
dministration Medical Center or the University of Cali-
ornia, San Diego Medical Center vascular laboratories
etween 1990 and 1994 (25). Inclusion criteria included a
istory of either “PAD,” defined by an ankle-brachial index
ABI) 0.90 or 1.4 in either leg or prior surgery/
ngioplasty for PAD in either leg, or “other CVD,” defined
y a history of myocardial infarction, percutaneous translu-
inal coronary angioplasty, coronary artery bypass graft
urgery, transient ischemic attack, or cerebrovascular acci-
ent. This ABI threshold has been shown to be 80%
ensitive and 97% specific for angiographically diagnosed
AD. The ABI for each leg was determined using the
easured ankle systolic pressure, determined by sphygmo-
anometric technique with detection at the toe by photo-
lethysmography, divided by the highest brachial blood
ressure between the 2 arms. Patients were not included if
hey could not be located to complete the initial interview or
efused participation. Of the 2,265 potential candidates for
he study, 481 were deceased and 1,276 could not be located
r declined invitation. Among the remaining subjects, 412
ubjects fulfilled the inclusion criteria for the study.
After informed consent, subject information concerning
emographic data, risk factors, and previous and current
ascular disease was determined by standardized subject
nterview, medical record review, primary care physician
uestionnaire, physical examination, and blood sample col-
ection. Participants provided written consent for participa-
ion in the studies and the use of their data for future
esearch. Institutional review board approval was obtained
rom the University of California, San Diego.
aboratory methods. At the baseline evaluation, blood
amples were collected from subjects into tubes containing
thylenediaminetetraacetic acid. Blood chemistries were
erformed at the time of collection using standardized
aboratory tests with the remainder of the blood being
tored at 70°C. The concentration of high-density li- voprotein (HDL) cholesterol was
etermined using a direct enzy-
atic colorimetric assay (26). The
rozen samples were thawed in
004 and analyzed for plasma
-terminal pro-B-type natriuretic
eptide (NT-proBNP) levels us-
ng a chemiluminescence sand-
ich immunoassay technology in
rray format (Pierce Search-
ight, Rockford, Illinois). Intra-
ssay and interassay precision
as 6.6% and 15%, respectively.
he linear range of detection of
his assay was 22 to 12,500 pg/
l. Plasma creatinine levels were
etermined using a kinetic Jaffe
ethod (Hitachi 917, Roche
harmaceuticals, Basel, Switzer-
and). Plasma GFR was calcu-
ated using the abbreviated Mod-
fication of Diet in Renal Disease
MDRD) formula, which uses se-
um creatinine, age, and race.
he MDRD formula has been
hown to be a more accurate
ndicator of true renal function,
ather than using a proxy such as
erum creatinine alone, and
hould particularly be used in populations with significant
enal insufficiency (27–29).
ortality ascertainment. The subjects were followed for
n average of 6.7 years until they either died or the end of
he study period on December 31, 2001. A certified nosol-
gist examined death certificates of all the subjects who died
nd coded their underlying and contributing cause of death
y International Classification of Diseases-Ninth Revision
ICD-9) code. Mortality from ischemic heart disease (IHD)
as defined using the ICD-9 code range of 410-414, and
ortality from any CVD was defined as ICD-9 code range
f 410-414 or 420-438.
tatistical methods. For purposes of analysis, in addition
o the analysis of the whole population, 3 subgroups were
efined: those with a history of other CVD and without
AD, those with a history of PAD and without other CVD,
nd those with a history of both PAD and other CVD. The
ubgroup of subjects with both PAD and other CVD
istories was the reference group for comparisons. We
ompared baseline descriptive characteristics across sub-
roups using t test for normally distributed continuous
ariables and a chi-square test for categorical variables.
dditionally, mean NT-proBNP and GFR levels between
he subgroups were compared using 1-way analysis of
ariance (ANOVA) tests. Significance was determined as p
Abbreviations
and Acronyms
ABI  ankle-brachial index
ACE  angiotensin-
converting enzyme
BNP  B-type natriuretic
peptide
CHF  congestive heart
failure
CVD  cardiovascular
disease
GFR  glomerular filtration
rate
HDL  high-density
lipoprotein
HR  hazard ratio
ICD-9  International
Classification of Diseases,
Ninth Revision
IHD  ischemic heart
disease
MDRD  Modification of
Diet in Renal Disease
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
PAD  peripheral arterial
diseasealue 0.05.
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GFR and Cardiovascular Mortality June 5, 2007:2172–81The association between predictor variables and mortality
nd points was evaluated using Cox regression analyses. The
T-proBNP levels were log-transformed to improve nor-
ality of distribution in the model. Covariates that were
ncluded in the model were based on Framingham criteria
or cardiovascular risk assessment outlined in the NCEP-
TPIII (National Cholesterol Education Program Expert
anel on Detection, Evaluation, and Treatment of High
lood Cholesterol in Adults) panel report: age, gender, total
holesterol, HDL cholesterol, whether the subject was a
urrent smoker, the systolic blood pressure, and whether
hey were currently taking antihypertensive medication (30).
e also controlled for diabetes and the use of medications
or dyslipidemia.
The NT-proBNP measurement was missing for 1
ubject (0.2%), and calculated GFR measurement could
ot be performed due to missing information in 9
ubjects (2.1%). To further characterize whether a
hreshold level existed for these prognostic variables,
egression analyses were performed using stratified NT-
roBNP and GFR levels. To increase comparability with
rior studies, we examined whether the prognostic rela-
ionship varied by follow-up time: 3 years, 5 years, or the
ull study duration (average 6.7 years). All analyses were
erformed using SPSS statistical software 14.0 (SPSS
nc., Chicago, Illinois).
aseline Characteristics Stratified by Total Population and Subgrou
Table 1 Baseline Characteristics Stratified by Total Population
Characteristic*
Total Populati
(n  412)
Age (yrs), mean  SD 69 9
Men 369 (90%)
Non-Hispanic white 358 (86.9%)
Current cigarette smoker 126 (31%)
Systolic blood pressure (mm Hg), mean  SD‡ 144 22
Currently taking medication for hypertension 263 (64%)
ACE inhibitor use 72 (18%)
Diuretic use 110 (27%)
Aspirin use 223 (54%)
Total cholesterol (mg/dl), mean  SD 209 42
HDL cholesterol (mg/dl), mean  SD 46 13
Currently taking medication for cholesterol 87 (21%)
Diabetes mellitus 131 (32%)
History of other cardiovascular disease 251 (61%)
History of peripheral arterial disease 354 (86%)
Glomerular filtration rate (ml/min/1.73 m2), mean  SD§ 56 15
NT-proBNP (pg/ml), mean  SD 510 810
Mortality
Time to mortality or study completion (days), mean  SD 2,442 1,19
All-cause mortality 254 (62%)
Ischemic cardiac death 128 (31%)
Cardiovascular death 207 (50%)
History of peripheral arterial disease (PAD) (ankle-brachial index 0.9 or1.4 or previous PAD
ransluminal coronary angioplasty, coronary artery bypass graft surgery, transient ischemic attack,
t test was used for normally distributed continuous variables and a chi-square test for categoricormula; ischemic cardiac death (ICD-9 code 410-414); any cardiovascular death (ICD-9 code 410-414 o
ACE  angiotensin-converting enzyme inhibitor; HDL  high-density lipoprotein; NT-proBNP  N-terminesults
he characteristics of the entire study population in addi-
ion to the characteristics of the three previously defined
ubgroups of patients are shown in Table 1. The population
as predominantly non-Hispanic white men. A significant
roportion of subjects were active smokers (31%), had
iabetes mellitus (32%), had elevated systolic blood pres-
ures (mean 144 mm Hg), or had borderline elevated total
holesterol (mean 209 mg/dl). Sixty-one percent had a
istory of other CVD, 86% had a history of PAD, and
7% had a history of both conditions. The subgroup of
atients with other CVD alone had significantly less active
mokers, lower systolic blood pressure, and a lower mean
otal cholesterol than patients who had a history of both
ther CVD and PAD. Twelve percent were taking an
ngiotensin-converting enzyme (ACE) inhibitor, 19% were
aking a diuretic, and 48% were taking aspirin. Similarly,
atients with PAD alone had significantly less use of
ntihypertensive medications and higher HDL levels than
he reference group. Similar proportions of patients were
sing the aforementioned medications. There was a signif-
cant difference in the mean GFR levels ( SD) between
he 3 subgroups of the population: other CVD and PAD
opulation (54  15 pg/ml), other CVD only population
58  15 pg/ml), PAD only population (59  15 pg/ml)
Subgroups
Both PAD and Other
CVD History (n  193)
Only Other CVD
History (n  58)
Only PAD History
(n  161)
70 9 69 9 69 9
177 (92%) 51 (88%) 141 (88%)
173 (89.6%) 51 (87.9%) 134 (83.2%)
60 (31%) 8 (14%)† 58 (36%)
147 23 135 19† 144 21
147 (76%) 36 (62%) 80 (50%)†
39 (20%) 7 (12%) 26 (16%)
64 (33%) 11 (19%)† 35 (22%)†
125 (65%) 28 (48%)† 70 (44%)†
210 42 202 41§ 211 42
44 12 46 12 48 15†
44 (23%) 11 (19%) 32 (20%)
64 (33%) 19 (33%) 48 (30%)
54 15 58 15 59 15†
490 589 411 262 570 1,110
2,236 1,199 2,579 1,180 2,638 1,168†
133 (69%) 32 (55%) 89 (55%)†
80 (42%) 16 (28%) 32 (20%)†
123 (64%) 22 (38%)† 62 (39%)†
y); history of other cardiovascular disease (CVD) (history of myocardial infarction, percutaneous
brovascular accident); †p  0.05 when compared patients with both PAD and other CVD histories;
bles; ‡measured in the highest arm; §calculated using the Modification of Diet in Renal Diseaseps
and
on
7
surger
or cere
al variar 420-438).
al pro-B-type natriuretic peptide.
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June 5, 2007:2172–81 GFR and Cardiovascular Mortalityp  0.01). The NT-proBNP levels showed no significant
ifference between subgroups.
Figure 1 shows the distributions of GFR levels between
he subgroups as well as information on mortality for these
roups. In the overall population, the mean GFR ( SD)
as 56  15 ml/min/1.73 m2. The population who died
rom any cause had significantly worse renal function than
hose who did not die (54 ml/min/1.73 m2 vs. 60 ml/min/
.73 m2, respectively, p  0.001). Similarly, those who
emained alive had significantly higher GFR than those
ho died of IHD (53 ml/min/1.73 m2, p  0.001) and
hose who died of any cardiovascular event (53 ml/min/1.73
2, p  0.001). A similar significant relationship was seen
n the subgroups with other CVD alone or with other CVD
nd PAD.
The NT-proBNP levels were also stratified between
ubgroups and according to cause of death (Fig. 2). In the
verall population, the mean NT-proBNP level ( SD) was
10 810 pg/ml. There was no significant difference in the
ean NT-proBNP levels between those who were alive
479 pg/ml) and those who died of any cause (530 pg/ml),
ied of IHD (466 pg/ml), or died of any cardiovascular
vent (479 pg/ml). In the subgroup analysis, there was no
ignificant difference in ln(NT-proBNP) levels between the
ubgroups of the population. Additionally, there was a
Figure 1 Glomerular Filtration Rate According to Population Su
Boxes show the 25th and 75th percentile with the mean shown. Whiskers repres
Modification of Diet in Renal Disease formula (ml/min/1.73 m2). Ischemic cardiac
death (ICD-9 code 410-414 or 420-438). CVD  history of nonperipheral arterial d
disease.onsignificant difference when ln(NT-proBNP) was strati- Ped by GFR category:45 (5.69), 45 to 59 (5.97), and60
l/min/1.73 m2 (5.93) (p 0.053 by ANOVA). There was
weakly positive and suggestive correlation between calcu-
ated GFR and NT-proBNP using Spearman’s rank order
orrelation (r 0.084, R2 0.0071, p  0.094) as shown in
igure 3. As shown in this scatterplot stratified by subgroup
nd mortality, at GFR levels below the mean, there was a
igher overall mortality within the other CVD/PAD and
ther CVD only subgroups. However, within the PAD only
ubgroup, mortality was more evenly distributed around the
ean GFR. Additionally, higher mortality above the mean
n(NT-proBNP) level was limited to the PAD only sub-
roup.
Table 2 shows the hazard ratio (HR) for all-cause
ortality, death from IHD, and death from any cardiovas-
ular event for NT-proBNP (per log unit) and GFR (per 10
l/min/1.73 m2) in the whole vascular population as well as
ts subgroups. In this vascular cohort, GFR was significantly
redictive of all-cause mortality (HR 0.81, p  0.001),
schemic cardiac death (HR 0.82, p  0.008), and any
ardiovascular death (HR 0.84, p 0.005). In patients with
ther CVD, GFR was predictive for all-cause mortality
HR 0.67, p  0.049), IHD death (HR 0.38, p  0.011),
nd all cardiovascular death (HR 0.61, p  0.063). Addi-
ionally, in patients with a history of both other CVD and
p and Cause of Death
times the interquartile range. Glomerular filtration rate calculated based on the
(International Classification of Diseases [ICD]-9 code 410-414); cardiovascular
cardiovascular disease; PAD  history of lower extremity peripheral arterialbgrou
ent 1.5
death
iseaseAD, GFR was significantly predictive of all-cause mortal-
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GFR and Cardiovascular Mortality June 5, 2007:2172–81ty (HR 0.79, p  0.003), IHD death (HR 0.82, p 
.042), and all cardiovascular death (HR 0.84, p  0.025).
s demonstrated in Figure 4, using pairwise log-rank
omparisons of Kaplan-Meier survival curves, a significant
ifference in cumulative survival was demonstrated between
ach GFR category for all-cause mortality. A significant
ifference in survival was seen between the lowest GFR
ategory and the 2 higher GFR categories for ischemic
ardiac mortality and any cardiovascular mortality.
Furthermore, after controlling for risk factors and renal
unction, NT-proBNP as a continuous variable was not a
ignificant predictor of all-cause mortality, ischemic car-
iac death, or any cardiovascular death in this vascular
opulation. In subgroup analyses, NT-proBNP levels
howed an association in patients with a history of PAD
nly: all-cause mortality (HR 1.30, p  0.054), ischemic
ardiac death (HR 1.47, p  0.103), or any cardiovascular
eath (HR 1.21, p  0.277) (Table 2). In patients who
ad other CVD, either alone or with PAD, NT-proBNP
as not significantly protective of any of the outcome
ariables. No significant threshold was found between
ertiles of NT-proBNP and all-cause mortality, ischemic
ardiac mortality, or any cardiovascular mortality.
aplan-Meier survival analysis did not show a significant
ifference between tertiles of NT-proBNP in cumulative
ll-cause mortality, ischemic cardiac death, or any car-
Figure 2 NT-proBNP Levels According to Population Subgroup a
Boxes show the 25th and 75th percentile with the mean shown. Whiskers repres
cardiovascular death (ICD-9 code 410-414 or 420-438). NT-proBNP  N-terminal piovascular death. fOn repeat analysis using 3- and 5-year cutoff periods,
here were no notable changes in the prognostic relationship
etween either GFR or NT-proBNP and the 3 outcome
ariables. The relationships found in the full-length sub-
roup analyses were similar as well.
iscussion
he utility of GFR and BNP in predicting all-cause and
ardiovascular mortality has been examined in a variety of
opulations, including limited vascular cohorts. However,
rior studies have exhibited various shortcomings, such as
xcluding patients with CHF, having limited follow-up
uration, and not fully stratifying by prior cardiovascular
istory, which has limited their applicability to a clinical
ascular population. To our knowledge, this study is the first
o demonstrate, in an unrestricted vascular population
tratified by the presence of PAD or other CVD, the
ssociation of GFR and NT-proBNP levels with long-term
ll-cause mortality, ischemic cardiac mortality, and mortal-
ty from any cardiovascular cause.
rimary outcome analysis. The relationship between
FR and all-cause mortality, specifically in populations
ith severe vascular disease, has been established. O’Hare
t al. (11) established in a large cohort of veterans with
ritical leg ischemia that GFR (estimated by the MDRD
ause of Death
times the interquartile range. Ischemic cardiac death (ICD-9 code 410-414);
pe natriuretic peptide; other abbreviations as in Figure 1.nd C
ent 1.5
ro-B-tyormula) was significantly predictive of 1-year all-cause
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June 5, 2007:2172–81 GFR and Cardiovascular Mortalityortality after controlling for confounders. Patients with a
FR 30 had nearly triple the risk of mortality than those
ith GFR 60. Furthermore, despite the coexistence of
iabetes and hypertension in populations with renal dys-
unction, the independent prognostic power of GFR has
een demonstrated previously in the PAD population (10).
ur study confirmed the relationship of lower GFR and
Figure 3 Correlation Between NT-proBNP and Glomerular Filtra
The linear regression equation for the entire population is ln(NT-proBNP)  5.61 
0.038 by Pearson correlation). Linear regression equations for subgroups did not
the horizontal line represents the mean ln(NT-proBNP) level. Abbreviations as in F
azard Ratios for Mortality According to Baseline NT-proBNP* and
Table 2 Hazard Ratios for Mortality According to Baseline NT-p
Entire Population Othe
HR p Value HR
Glomerular filtration rate (per 10 ml/min/1.73 m2)
All-cause mortality 0.81 0.001 0.67
Ischemic cardiac death 0.82 0.008 0.38
Any cardiovascular death 0.84 0.005 0.61
NT-proBNP level (per log unit)
All-cause mortality 1.11 0.264 1.48
Ischemic cardiac death 1.02 0.900 0.82
Any cardiovascular death 1.04 0.720 0.99
NT-proBNP standardized by natural log transformation; †the model included age, gender, current
igh-density cholesterol, whether taking medication for cholesterol, NT-proBNP level, and glomerula
VD or PAD. Ischemic cardiac death (ICD-9 code 410-414); any cardiovascular death (ICD-9 code 410-41
HR  hazard ratio; other abbreviations as in Table 1.ncreased all-cause mortality in a population with a wide
ange of vascular disease severity. Additionally, we demon-
trated that patients with progressive renal dysfunction are
t a significantly increased risk of cardiovascular death and
pecifically ischemic cardiac death. The mechanism of this
elationship is poorly understood, although the associated
xtracellular volume overload, increased oxidative stress,
ate According to Subgroup and Mortality
(glomerular filtration rate) and shown in the graph (r  0.104, R2  0.011, p 
ignificantly. The vertical line represents the mean glomerular filtration rate and
1 and 2.
erular Filtration Rate†
P* and Glomerular Filtration Rate†
Only PAD Only
Both Other CVD
and PAD
p Value HR p Value HR p Value
0.049 0.89 0.165 0.79 0.003
0.011 0.93 0.636 0.82 0.042
0.063 0.94 0.579 0.84 0.025
0.279 1.30 0.054 0.94 0.652
0.701 1.47 0.103 0.89 0.504
0.978 1.21 0.277 0.98 0.887
g, diabetes, systolic blood pressure, whether taking antihypertensive medication, total cholesterol,
ion rate; the model on the entire population also included variables to control for a history of othertion R
0.01
differ s
igures Glom
roBN
r CVD
smokin
r filtrat4 or 420-438).
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GFR and Cardiovascular Mortality June 5, 2007:2172–81lectrolyte imbalances, and anemia in patients with chronic
enal dysfunction have all been proposed (17,31). Alterna-
ively, the differential use of ACE inhibitors, aspirin,
hrombolytics, percutaneous intervention, or platelet in-
ibitors in these patients has been proposed (32). Inter-
stingly, in our study population, there was no significant
ifference in aspirin use by GFR tertile. Although there
as a significant difference in ACE inhibitor use by GFR
ertile, after controlling for its use, GFR remained
trongly predictive of all-cause and any cardiovascular
ortality.
The utility of BNP and NT-proBNP in predicting
utcomes in various populations has also received consider-
ble attention in recent years. In a landmark paper, Wang et
Figure 4 Overall Survival Among All Patients According to Mor
Green  glomerular filtration rate 60 ml/min/1.73 m2; yellow  glomerular filtra
59 ml/min/1.73 m2; blue  glomerular filtration rate 45 ml/min/1.73 m2. Coml. (5) described how BNP was predictive of death indepen- hent of traditional risk factors in a community population,
ut was not predictive of future coronary heart disease
vents. These findings were later supported in an older adult
ommunity population (8). Both of these studies excluded
atients with evidence of CHF or renal insufficiency.
tudies soon looked to examine whether a similar prognos-
ic power exists in patients with a history of CVD. Krage-
und et al. (9) examined whether NT-proBNP possessed
ong-term prognostic power in a population of patients with
inimal renal impairment, referred for elective angiography
or signs or symptoms or coronary artery disease. They
ound that, independent of traditional risk factors or calcu-
ated creatinine clearance, NT-proBNP levels were signifi-
antly predictive of all-cause mortality. Similar findings
Cause and Glomerular Filtration Rate
ate 45 to
ns made by pairwise log-rank tests.tality
tion r
parisoave been seen in predicting myocardial infarction based on
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June 5, 2007:2172–81 GFR and Cardiovascular MortalityT-proBNP populations with cerebrovascular disease and
ithout CHF (6). In the recently published HOPE (Health
utcomes Prevention Evaluation) study, using a vascular
opulation without heart failure, overt nephropathy, or
ecent myocardial infarction/cerebrovascular accident, and
ontrolling for traditional risk factors in addition to creati-
ine level, researchers found that NT-proBNP was predic-
ive of the combined outcome of myocardial infarction,
erebrovascular accident, or cardiovascular death over a
ean 4.5-year follow-up duration.
Of particular note, our findings suggest that the prognos-
ic power of NT-proBNP seen in other populations may be
ignificantly attenuated in a less selective vascular popula-
ion, with a high prevalence of PAD, CVD, renal, and
ardiac dysfunction. Several important differences distin-
uish our study from previous ones. First, the relationship
etween NT-proBNP and CHF is well established, and the
revalence of CHF is estimated between 40% to 60% in
ome vascular populations (9,33). Hence, the elimination of
atients with CHF from other study populations makes the
esults difficult to truly extend to the full vascular spectrum.
econdly, as discussed earlier, in patients with a significant
egree of renal insufficiency (mean  SD GFR 56  15
l/min/1.73 m2 in our population) and obesity (mean 
D body mass index 27  8 kg/m2 in our population),
he better estimation of true renal function is the use of
he MDRD formula (27,34). Many prior studies have
ither used calculated creatinine clearance rate using the
ockcroft-Gault equation, or simply used serum creatinine
evels. Given the interdependence of NT-proBNP levels
nd renal function and demonstrated independent prognos-
ic power of GFR on mortality, suboptimal adjustment for
enal function may falsely enhance the predictive power of
T-proBNP (24). Finally, the mean levels of NT-proBNP
n this population were significantly higher than prior
tudies (512 pg/ml vs. 144 pg/ml in the HOPE study) likely
eflecting worse cardiovascular dysfunction in our popula-
ion. We feel that these differences may account for the
bsence of consistent prognostic power for NT-proBNP in
his population.
In this population, we did not observe the expected
egative correlation between GFR and NT-proBNP as has
een described in other populations (14,15,35). Although
here was only a weak correlation between the 2 variables,
his relationship did not change with correction for age,
ender, diuretic use, or other potential confounders. This
elationship may be a result of the large proportion of
atients with PAD in this study (86%) compared with
thers (typically 20%) as well as the higher levels of
T-proBNP observed in patients with PAD (vs. age- and
ender-matched control subjects) (36,37). However, given
he relatively little known about GFR and NT-proBNP in
AD populations, future examination of this topic in this
roup is certainly warranted.
ubgroup analysis. The subgroup analysis of renal func-ion and mortality was of particular interest. Prior studies fave demonstrated that, in high-risk populations with
VD, such as those with heart failure, postacute coronary
yndrome, and postcoronary bypass surgery, GFR is predic-
ive of mortality (32). Furthermore, a limited number of
tudies have examined whether this concept can be applied
o the entire vascular population. Mlekusch et al. (10)
emonstrated in a vascular cohort that, independent of
raditional cardiovascular risk factors, subjects with the
owest GFR quartile (44.8) had nearly a 7 times greater
azard of mortality than those with the highest GFR
82.7). However, this and other similar studies did not
epeat the analysis after exclusion of the 45% with known
VD and 23% with a history of myocardial infarction. To
ur knowledge, our study is the first to answer this question.
Our findings do confirm that in the whole vascular
opulation, as well as the subgroup with known other CVD
either other CVD alone or both other CVD and PAD),
ower GFR conferred a significant or strongly suggestive
ncreased hazard of all-cause, cardiovascular, and ischemic
ortality. However, when this subgroup was excluded from
he analysis, the predictive power of GFR on mortality
ailed to persist in subjects with PAD alone. These findings
re in line with prior studies of community populations with
relatively low prevalence or with exclusion of patients with
nown CVD (38,39). Our findings support the concept
hat, in patients with only PAD, renal insufficiency may be
imply a marker of underlying cardiovascular risk factors
ather than an independent risk factor for cardiovascular or
ll-cause mortality. However, further research needs to be
erformed to better examine this question.
In the subgroup analysis, NT-proBNP showed the stron-
est prognostic ability in the population with only PAD,
ith an increased risk approaching significance of all-cause
ortality and ischemic cardiac death. This finding is in
oncordance with other studies of other general and clinical
opulations suggesting an increased risk of all-cause mor-
ality and ischemic cardiac mortality with higher levels of
T-proBNP. Furthermore, this finding is supportive of the
heory that, in patients with underlying CVD, likely directly
nvolving the heart, there is a greater likelihood of other
actors, such as the presence of CHF or the concomitant use
f diuretics/angiotensin receptor blockers, which can inde-
endently alter BNP and attenuate its prognostic power
40). Additionally, the differential prognostic role according
o subgroup suggests the possibility that the prognostic
ower of NT-proBNP demonstrated in other studies may in
act be a proxy for the strong role of renal dysfunction,
articularly given the inadequate or absent adjustment for
enal function in multivariate analyses. Similarly, it is
ossible that given the strong hazard risk conferred by
orsening renal function in populations with CVD, the
ndependent effect of NT-proBNP may be attenuated in
his subgroup.
tudy strengths and limitations. The strengths of this
tudy include its prospective design, the use of ICD-9 codes
or mortality classification, longer duration of follow-up, use
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ent examination of subgroups according to CVD history.
owever, some limitations include that the study popula-
ion was predominantly comprised of non-Hispanic white
ale veterans and was relatively small compared with larger
ulticenter cohorts. Hence, it is unclear whether these
ndings can be extended to other populations, such as
frican Americans. Additionally, as described in the pre-
eding text, though the MDRD formula for GFR calcula-
ion is more accurate in the setting of renal insufficiency
han serum creatinine or that calculated by the Cockcroft-
ault formula, the study is limited by the singular measure-
ent of GFR and BNP rather than a multiple measure-
ents over time.
Finally, an estimation of cardiac function would have
rovided a useful backdrop, particularly for BNP interpre-
ation, in patients with suspected CHF and potentially
arying volume status. However, there is extensive research
n this field demonstrating the prognostic power of BNP
ndependent of left ventricular function. Brain natriuretic
eptide has been shown to be predictive of mortality in
ommunity populations without heart failure or after con-
rolling for evidence of heart failure at the time of enroll-
ent (5,41). Additionally, multiple studies, including those
ecently published by Rothenbacher et al. (42) examining
atients with known coronary artery disease, have demon-
trated that BNP is predictive of cardiovascular mortality
ndependent of left ventricular function (9). Thus, we would
ot expect left ventricular function data to have significantly
ffected our results.
onclusions
n a vascular population at high risk of overall mortality,
FR was a more robust predictor of all-cause, overall
ardiovascular mortality, and ischemic cardiac mortality
han NT-proBNP levels. In particular, our findings suggest
FR has its strongest role in the subset of the vascular
opulation with a known history of prior coronary artery or
erebrovascular disease. The prognostic utility of NT-
roBNP in the vascular population requires further exami-
ation, although its role may be greatest in the subset of the
opulation with isolated PAD. A better understanding of
he utility and role of these 2 prognostic markers will help
hysicians better risk-stratify their patients and target ther-
pies accordingly.
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